Phase 1 Trial: Stem Cell Treatment for Parkinson’s
- A pioneering phase 1 open-label clinical trial at Mass General Brigham is making waves in the treatment of Parkinson's disease.
- The groundbreaking study has already enrolled and treated three participants at Brigham and Women’s Hospital, marking a notable step forward in the fight against Parkinson's.
- The phase 1 study represents a significant milestone as the first trial to test blood-derived autologous iPSC-derived dopamine neurons in patients with Parkinson's disease.
Groundbreaking Clinical Trial Tests Novel Stem Cell Treatment for Parkinson’s Disease
Table of Contents
- Groundbreaking Clinical Trial Tests Novel Stem Cell Treatment for Parkinson’s Disease
- Stem Cell Therapy for Parkinson’s Disease: Your questions Answered
- What is the New Stem Cell Therapy for Parkinson’s Disease?
- How Dose This Stem Cell Therapy Work?
- What are induced pluripotent stem cells (iPSCs)?
- What is unique about this clinical trial’s approach?
- What phase is this clinical trial?
- What Does Phase 1 Mean?
- How many participants are in this Phase 1 trial?
- Where is the clinical trial taking place?
A pioneering phase 1 open-label clinical trial at Mass General Brigham is making waves in the treatment of
Parkinson’s disease. The study evaluates an innovative approach that uses a patient’s own reprogrammed
stem cells to replace dopamine neurons damaged by the disease. This treatment aims to directly address the
underlying neuronal loss and restore crucial dopamine function.
The groundbreaking study has already enrolled and treated three participants at Brigham and Women’s Hospital, marking a
notable step forward in the fight against Parkinson’s.
The Promise of Personalized Stem Cell Therapy
The phase 1 study represents a significant milestone as the first trial to test blood-derived autologous iPSC-derived
dopamine neurons in patients with Parkinson’s disease. The trial will include a total of six participants and is
designed to monitor their progress for at least 12 months. Researchers will meticulously assess the safety and potential
benefits of this innovative procedure. The study receives funding from the National institute of Health’s National
Institute of Neurological Disorders and Stroke.
The treatment,developed at McLean Hospital’s Neuroregeneration Research Institute (NRI),leverages induced pluripotent
stem cells (iPSC) derived from a patient’s blood. Thes cells are reprogrammed into midbrain
dopaminergic neurons, which are the very cells that degenerate in Parkinson’s disease. by utilizing the
patient’s own cells, the approach effectively eliminates the risk of immune rejection.
The US Food and Drug Management granted Investigational New Drug approval for the phase 1 trial on August 23, 2023,
and the first patient was treated on September 9, 2024. If the initial results are promising, researchers plan to expand
the study into a phase 2A trial to recruit additional participants and further explore the potential of this therapy.
“Seeing this patient-specific dopamine neuron replacement therapy progress from basic research to clinical application is
incredibly gratifying,”Ole Isacson, MD, the founding director of the NRI
Isacson further stated, “We believe this approach may open up a new treatment paradigm and lead to the development of
many additional cell therapies to restore damaged brain systems and replace degenerated brain cells in other diseases.”
Decades of Research Paving the Way
This groundbreaking research builds upon decades of dedicated work. in 2015, research contributed to the first study
providing evidence of the safety and efficacy of autologous stem cell therapy in a nonhuman primate model. The
most accomplished model from that study demonstrated that unilateral engraftment of a cynomolgus monkey iPSCs could provide
a gradual onset of functional motor improvement and increased motor activity without the need for immunosuppression.
A 2020 study examined the advantages of autologous cell therapy for patients with Parkinson’s disease.
Osborn et al wrote that “When new midbrain dopamine (mDA) neurons… are engrafted into the normal target regions of
nigrostriatal dopamine (DA) neurons, they establish synapses with mature host striatal neurons and provide
physiologically appropriate DA release and synaptic feedback control in the host brain.”
Osborn et al
The authors concluded that the replacement of DA terminals in this manner may be more effective in bettering the motor
symptoms in Parkinson’s disease. Osborn et al also found that long term benefits to patients with
Parkinson’s disease following fetal DA neuron transplantation have been reported for over 18 years and can
prevent progressive worsening of motor scores over at least 14 years.
Key Takeaways
- First-of-its-kind phase 1 clinical trial at Mass general Brigham.
- Uses patient’s own reprogrammed stem cells.
- Aims to restore dopamine function in Parkinson’s disease.
- Builds on decades of research and previous successful models.
Timeline of Key events
| Date | Event |
|---|---|
| August 23, 2023 | FDA granted Investigational new Drug approval |
| September 9, 2024 | First patient treated |
| March 6, 2025 | News release about the clinical trial |
Stem Cell Therapy for Parkinson’s Disease: Your questions Answered
parkinson’s disease is a neurodegenerative disorder affecting millions worldwide. Recent advancements in stem cell therapy offer hope for a potential new treatment paradigm. This Q&A explores a groundbreaking clinical trial at Mass General Brigham, investigating a novel stem cell treatment for Parkinson’s disease.
What is the New Stem Cell Therapy for Parkinson’s Disease?
This new experimental therapy involves using a patient’s own reprogrammed stem cells to replace damaged dopamine neurons in the brain. The goal is to restore dopamine function, which is crucial for motor control and is impaired in Parkinson’s disease. This approach is designed to address the underlying cause of the disease by replacing the cells that are lost or damaged.
How Dose This Stem Cell Therapy Work?
The therapy uses induced pluripotent stem cells (iPSCs) derived from a patient’s blood. Here’s a breakdown:
Blood Sample: A blood sample is taken from the patient.
Reprogramming: The cells in the blood are reprogrammed into iPSCs. These iPSCs have the potential to become any cell type in the body.
Differentiation: The iPSCs are then differentiated into midbrain dopaminergic neurons, the specific type of brain cell that is affected by Parkinson’s disease.
Transplantation: These newly created dopamine neurons are transplanted back into the patient’s brain.
Restoration: The transplanted cells are intended to replace the damaged neurons and restore dopamine production, thereby alleviating motor symptoms of Parkinson’s disease.
What are induced pluripotent stem cells (iPSCs)?
induced pluripotent stem cells (iPSCs) are a type of stem cell that are artificially derived from adult somatic cells by inducing a ”forced” expression of specific genes. These genes, often called transcription factors, can reprogram the somatic cells into a pluripotent state, similar to that of embryonic stem cells.
What is unique about this clinical trial’s approach?
The groundbreaking aspect of this trial lies in its personalized approach. By using a patient’s own reprogrammed stem cells, the risk of immune rejection is virtually eliminated. This contrasts with other stem cell therapies that may use cells from donors, requiring immunosuppressant drugs to prevent rejection.
What phase is this clinical trial?
This clinical trial is in Phase 1.
What Does Phase 1 Mean?
Phase 1 trials are the first stage of testing a new treatment in humans. The primary goals of a Phase 1 trial are to:
Assess Safety: Determine if the treatment is safe for humans and identify any potential side effects.
Determine Dosage: Find the appropriate dosage of the treatment.
observe How the Body Reacts: Monitor how the body absorbs, distributes, metabolizes, and eliminates the treatment.
Phase 1 trials typically involve a small number of participants, frequently enough healthy volunteers or individuals with the targeted disease who have tired other treatment options.
How many participants are in this Phase 1 trial?
The Phase 1 trial initially involves six participants. Three participants have already been enrolled and treated.
Where is the clinical trial taking place?
the clinical trial is taking place at Mass General Brigham, specifically at Brigham and Women